OTC Markets OTCPK - Delayed Quote ? USD Zealand Pharma A/S (ZLDPF) Follow Compare 118.50 +1.70 (+1.46%) At close: October 22 at 3:17 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom The future of the weight loss market might not revolve around GLP-1 drugs. Motley Fool ? 9 days ago ZEAL.CO Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s designed to work differently from those currently on the market and with the potential for fewer side effects. Quartz ? 11 days ago NVO ZEAL.CO FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants The regulator sought additional analyses from existing continuous glucose monitoring data collected during Phase III trials. Pharmaceutical Technology ? 13 days ago ZEAL.CO Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for dasiglucagon in CHI for up to three weeks of dosing due to the timing of a third-party manufacturing facility reinspectionThe reinspection of the facility was completed in August/September 2024 for which a new inspection classification is pendingZealand remains committed to working with GlobeNewswire ? 14 days ago ZLDPF +1.46% Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide Company announcement – No. 47 / 2024 Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II study Boehringer launches two Phase III studies of survodutide, L GlobeNewswire ? 14 days ago ZLDPF +1.46% Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Copenhagen, Denmark, September 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end GlobeNewswire ? 22 days ago ZLDPF +1.46% Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Press Release – No. 9 / 2024 Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th Copenhagen, Denmark, September 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Medical Officer, David Kendall, MD, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference at 9:10 a.m. ET (3:10 p.m. CET) on Wednesday, Sep GlobeNewswire ? last month ZLDPF +1.46% Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 10,110 divided into 10,110 new shares with a nominal value of DKK 1 each. The i GlobeNewswire ? last month ZLDPF +1.46% Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Placebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly dosesDapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapie GlobeNewswire ? last month ZLDPF +1.46% Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securit GlobeNewswire ? last month ZLDPF +1.46% Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Copenhagen, Denmark, August 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calen GlobeNewswire ? last month ZLDPF +1.46% This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk. Motley Fool ? last month NVO ZEAL.CO This Rising Biotech Is a Fantastic Weight-Loss Stock to Buy Now Its pipeline is one of the best among weight loss-focused biotechs right now. Motley Fool ? 2 months ago ZEAL.CO Zealand Pharma rebound after prior session losses Shares in Zealand Pharma (CSE:ZELA) rose on Tuesday, recovering losses from the previous session which came in the wake of comments by the company's CEO about seeking a large pharmaceutical partner for the company’s weight loss drug. At 5:02 am (0902 GMT), Zealand Pharma was trading 3.8% higher at DKK 943.50. Analysts at Jefferies have highlighted the company’s promising amylin pipeline and potential for lucrative partnerships as key drivers for the share price increase. Investing.com ? 2 months ago ZEAL.CO Zealand Pharma major shareholder announcement: Bank of America Corporation Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America Corporation Copenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports prior receipt on 19 March 2024 and 5 April 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major GlobeNewswire ? 2 months ago ZLDPF +1.46% Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance Zealand is using a recent $1 billion equity raise to “accelerate” several would-be weight loss medicines. Meanwhile, Bluebird reworked a loan and Boundless Bio cut jobs only months after an IPO. BioPharma Dive ? 2 months ago ARWR ZEAL.CO Zealand Pharma Announces Financial Results for the First Half of 2024 Company announcement - No. 39 / 2024 Zealand Pharma Announces Financial Results for the First Half of 2024 Very strong progress across R&D pipeline followed by substantial capital raise enabling further investments to accelerate the development programs for wholly owned obesity assets. Extremely encouraging weight loss and tolerability data announced with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial)Impressive data from Boehringer Ingelheim’s Phase 2 clinical trial with GlobeNewswire ? 2 months ago ZLDPF +1.46% Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 15, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the firs GlobeNewswire ? 2 months ago ZLDPF +1.46% Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma Both companies have a clear path to competing successfully in the market. Motley Fool ? 2 months ago VKTX ZEAL.CO Zealand Pharma Appoints Eric Cox as Chief Commercial Officer Press release – 7 / 2024 Zealand Pharma Appoints Eric Cox as Chief Commercial Officer Copenhagen, Denmark, 29 July 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Eric Cox as Zealand’s Chief Commercial Officer starting August 5, 2024. Eric will join the executive team to lead Zealand’s commercial strategy and assume responsibility for GlobeNewswire ? 2 months ago ZLDPF +1.46% Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index Return ZLDPF OMX Copenhagen 25 Index YTD +112.94% +5.66% 1-Year +181.21% +19.38% 3-Year +274.41% -1.16%
